MedTrace Logo

VPD-737 for Treatment of Chronic Pruritus

NCT01951274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2022-05-13

No results posted yet for this study

Summary

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Conditions

  • Chronic Pruritus

Interventions

DRUG

VPD-737

NK1 Receptor Antagonist

DRUG

Placebo

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Edward F Schnipper, MD · Acting Chief Medical Officer, Tigercat Pharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-15
Primary Completion
2014-12-02
Completion
2014-12-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01951274 on ClinicalTrials.gov